The estimated Net Worth of Todd Franklin Watanabe is at least 11.6 百万$ dollars as of 2 August 2024. Mr. Watanabe owns over 14,487 units of Arcutis Biotherapeutics Inc stock worth over 8,902,687$ and over the last 5 years he sold ARQT stock worth over 1,533,921$. In addition, he makes 1,140,300$ as President、 Chief Executive Officer、 Director at Arcutis Biotherapeutics Inc.
Todd has made over 42 trades of the Arcutis Biotherapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 14,487 units of ARQT stock worth 130,673$ on 2 August 2024.
The largest trade he's ever made was exercising 59,525 units of Arcutis Biotherapeutics Inc stock on 31 May 2023 worth over 100,002$. On average, Todd trades about 5,119 units every 33 days since 2020. As of 2 August 2024 he still owns at least 846,263 units of Arcutis Biotherapeutics Inc stock.
You can see the complete history of Mr. Watanabe stock trades at the bottom of the page.
Todd Franklin Watanabe serves as President, Chief Executive Officer, Director of the Company. Prior to joining Arcutis Biotherapeutics, he served as co-founder and Chief Operating Officer of Kanan Therapeutics, Inc., a cardiovascular drug development company from December 2015 to February 2018, and before that, he served as Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals Inc. from October 2013 to November 2015. Mr. Watanabe was an executive at Amgen, Inc. from 2005 to 2013, where he was involved in the development of Repatha for hyperlipidemia and Aimovig for migraine, and worked on the U.S. marketing of Enbrel in both dermatology and rheumatology. Previously, he was an executive with Eli Lilly and company, and an official in the U.S. Government. He was also a commissioned officer in the U.S. Navy Reserves for 25 years. Mr. Watanabe received his M.A. in National Security Studies, and his B.A. in International Relations, both from Georgetown University. Watanabe is qualified to serve on our board of directors because of his experience
As the President、 Chief Executive Officer、 Director of Arcutis Biotherapeutics Inc, the total compensation of Todd Watanabe at Arcutis Biotherapeutics Inc is 1,140,300$. There are no executives at Arcutis Biotherapeutics Inc getting paid more.
Todd Watanabe is 52, he's been the President、 Chief Executive Officer、 Director of Arcutis Biotherapeutics Inc since 2017. There are 14 older and 14 younger executives at Arcutis Biotherapeutics Inc. The oldest executive at Arcutis Biotherapeutics Inc is Howard Welgus, 68, who is the Director.
Todd's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361.
Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over 33,184,604$ worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth 71,202,175$ . The most active insiders traders include Jonathan Silverstein、Patrick J Heron、Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of 361,425$. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth 107,700$.
arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.
Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include: